Disclaimer:
1.This article is a repost and is provided for informational purposes only. The content does not reflect the views or opinions of 2Firsts.
2.Readers should rely on official company announcements and publicly available market data as the primary sources of information.
3.Nothing in this article should be construed as investment advice.
2Firsts reposts from Smartkarma Finance, August 28, 2025 —— Smoore International (06969) continued to fall following its earnings announcement, dropping more than 6% in early trading today. As of press time, it was down 5.08% at HK$19.23, with turnover reaching HK$466 million.
In terms of financials, Smoore reported interim results showing revenue of RMB 6.013 billion for the first half, up 18.3% year-on-year; adjusted net profit of RMB 737 million, down 2.1% year-on-year; and net profit of RMB 492 million, down 27.96% year-on-year. The interim dividend was HK$0.20 per share, compared to HK$0.05 in the same period last year. Bank of America Securities noted that Smoore’s performance was broadly in line with expectations. It forecast that full-year revenue growth would improve slightly, but profit margins would remain under pressure.
UBS released a research note pointing out that Smoore’s interim net profit decline was mainly due to higher share-based compensation, increased sales and development expenses, as well as higher taxes. Management remains optimistic about sustained revenue growth in the second half, supported by favorable vaping policies in the U.S. and Europe, but short-term profitability will continue to be pressured by higher R&D spending as the company prepares to launch its own products in the U.S. According to management, concrete financial results from new business segments—such as heated tobacco, inhalation therapies, and beauty atomization products—will not be reflected until 2027. UBS lowered its earnings forecast for 2025–2027 by 10%–33% to reflect higher sales, marketing, and R&D costs, cut its target price from HK$14.00 to HK$13.11, and maintained a “Sell” rating.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
